

## Kidney

### Metastatic

### Adjuvant

#### First Line

#### Second Line

#### Third Line

#### Papillary

#### Sarcomatoid

#### High Risk

[RENAL0033](#)  
Phase III Nivolumab + Ipilimumab vs Sunitinib Monotherapy in Untreated Advanced or Metastatic RCC

PI: Srinivas  
Bristol-Myers Squibb

Not Eligible for Immune Therapy

**RENAL0031**  
Phase II Alternative Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

PI: Srinivas  
(Pending)

[RENAL0030](#)  
Phase II Dalantercept + Axitinib Compared to Placebo + Axitinib in Advanced Renal Cell Carcinoma

PI: Srinivas  
Acceleron

[RENAL0027](#)  
Pilot Local Tumor Irradiation with Autologous T-Cell Infusion for Metastatic Renal Cell Carcinoma

PI: Srinivas  
Stanford

[RENAL0032](#)  
Phase II Study of AZD6094 (HMPL-504) in Papillary Renal Cell Carcinoma (PRCC)

PI: Srinivas  
AstraZeneca

No Prior Treatment

[ECOG1808](#)  
Phase II Sunitinib/ Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma w/ Sarcomatoid Features

PI: Srinivas  
ECOG

[RENAL0029](#)  
Phase III Adjuvant Axitinib vs Placebo in High Risk Recurrent Renal Cell Cancer

PI: Srinivas  
SFJ Pharmaceuticals

### KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study